TTR and cardiomyopathy: Current therapeutic strategies targeting TTR synthesis, secretion, and extracellular aggregation, such as liver transplantation, TTR gene silencers (including RNA interference therapies [Patisiran and Vutrisiran] and antisense oligonucleotides [Inotersen]), and TTR stabilizers (including Tafamidis, Difunisal, and Acoramidis) are only applicable for treating ATTRv polyneuropathy or ATTRv cardiomyopathy (Adams et al., 2023; Ando et al., 2022).